Abeona Therapeutics to Present at the Jefferies Healthcare Conference
June 06 2022 - 7:30AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader
in cell and gene therapy, today announced that company management
is scheduled to present at the Jefferies Healthcare Conference on
Thursday, June 9, 2022, at 3:30 p.m. EDT.
A live webcast of the presentation will be available on the
Investors section of the Abeona website under "Events" at
https://investors.abeonatherapeutics.com/events. The webcast will
be archived for 30 days.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for serious diseases.
Abeona’s lead clinical program is EB-101, its investigational
autologous, gene-corrected cell therapy for recessive dystrophic
epidermolysis bullosa in Phase 3 development. The Company’s
development portfolio also features AAV-based gene therapies for
ophthalmic diseases with high unmet medical need. Abeona’s novel,
next-generation AAV capsids are being evaluated to improve tropism
profiles for a variety of devastating diseases. Abeona’s fully
integrated cell and gene therapy cGMP manufacturing facility
produces EB-101 for the pivotal Phase 3 VIITAL™ study and is
capable of clinical and potential commercial production of
AAV-based gene therapies. For more information, visit
www.abeonatherapeutics.com.
Forward-Looking Statementsthat
are forward-looking within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and that involve risks
and uncertainties. We have attempted to identify forward-looking
statements by such terminology as “may,” “will,” “believe,”
“estimate,” “expect,” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, numerous risks and uncertainties,
including but not limited to, our ability to regain compliance with
the $1.00 minimum bid price requirement for continued listing on
The Nasdaq Capital Market; the potential impacts of the COVID-19
pandemic on our business, operations, and financial condition;
continued interest in our rare disease portfolio; our ability to
potentially commercialize our EB-101 product candidate; our ability
to enroll patients in clinical trials; the outcome of any future
meetings with the U.S. Food and Drug Administration or other
regulatory agencies; the impact of competition; the ability to
achieve or obtain necessary regulatory approvals; the impact of
changes in the financial markets and global economic conditions;
risks associated with data analysis and reporting; reducing our
operating expenses and extending our cash runway; our ability to
execute our operating plan and achieve important anticipated
milestones; and other risks disclosed in the Company’s most recent
Annual Report on Form 10-K and other periodic reports filed with
the Securities and Exchange Commission. The Company undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024